Faculty Summaries
Jeff Boyd, PhD
Jeff Boyd, PhD
Professor
  • Senior Vice President, Molecular Medicine
  • The Robert C. Young, MD, Chair in Cancer Research
  • Executive Director, Cancer Genome Institute
  • Chief, Division of Molecular Pathology
  • Professor, Cancer Biology Program
Jeff.Boyd@fccc.edu
Office Phone: 215-728-2907
Lab Phone: 215-214-4053
Office: R252
Lab: R354

Peer-Reviewed Publications (2000-present)

  • Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, Robson ME, Offit K, Barakat RR, Boyd J. Genetic analysis of the early natural history of ovarian carcinoma. PLoS ONE. 2010; e10358. PLoS ONE
  • Dong X-Y, Guo P, Boyd J, Sun X, Li Q, Zhou W, Dong J-T. Implication of snoRNA U50 in human breast cancer. J Genet Genomics. 2009;36:447-54. PubMed
  • Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, Rubin SC, Boyd J, Gimotty PA, Coukos G. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer. 2009;115:2891-902. PubMed
  • Berchuck A, Iverson ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009;15:2448-55. PubMed
  • Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D’Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008;14:7878-83. PubMed
  • Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett, JC, Boyd J, Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68:5478-86. PubMed
  • Gold B, Kirchhoff T, Stefanov S, Lautenberger J, Viale A, Garber J, Friedman E, Narod S, Olshen A, Gregersen P, Kosarin K, Olsh A, Bergeron J, Ellis NA, Klein R, Clark AG, Norton L, Dean M, Boyd J, Offit K. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci USA. 2008;105:4340-5. PubMed
  • Olshen AB, Gold B, Lohmueller KE, Struewing JP, Satagopan J, Stefanov SA, Eskin E, Kirchhoff T, Lautenberger JA, Friedman E, Norton L, Ellis NA, Viale A, Lee CS, Borgen PI, Clark AG, Offit K, Boyd J. Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics. 2008;9:14. PubMed
  • Edwards SL, Brough R, Lord CJ, Natrajan R, Levine DA, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111-5. PubMed
  • Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphologic features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39:116-25. PubMed
  • Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, Lee JB, Hudis C, Offit K, Robson M. BRCA mutations in women with ductal carcinoma in situ: prevalence and risk factors. Clin Cancer Res. 2007;13:4306-10. PubMed
  • King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, Boyd J. BRCA haploinsufficiency in human breast tumorigenesis. Ann Surg Oncol. 2007;14:2510-8. PubMed
  • Adank MA, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ, Meijers-Heijboer EJ, Kauff ND, Boyd J, Offit K. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer. 2006;5:337-42. PubMed
  • Black D, Soslow RA, Levine DA, Tornos C, Chen SC, Hummer AJ, Bogomolniy F, Olvera N, Barakat RR, Boyd J. The clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol. 2006;24:1745-53. PubMed
  • Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271-84. PubMed
  • Ferguson SE, Olshen AB, Levine DA, Viale A, Barakat RR, Boyd J. Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol. 2006;101:209-13. PubMed
  • Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, MacGillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. The characterization of a recurrent germline mutation of the E-Cadherin gene: Implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:;5401-9. PubMed
  • Spentzos D, Levine DA, Kolia S, Out H, Boyd J, Libermann T, Cannistra SA. Unique gene expression profile based upon pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005;23:7911-8. PubMed
  • Jazaeri AA, Awtrey CS, Gadisetti CVR, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett CJ, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11:6300-10. PubMed
  • Zorn KK, Gangi L, Chandramouli GVR, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-30. PubMed
  • Levine DA, Bogomolniy F, Yee C, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005;11:2875-8. PubMed
  • Abu-Rustum NR, Su W, Levine DA, Boyd J, Sonoda Y, LaQuaglia MP. Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach. Gynecol Oncol. 2005;97:296-300. PubMed
  • Ferguson SE, Olshen AB, Viale A, Barakat RR, Boyd J. Stratification of intermediate risk endometrial cancer patients into groups at high- or low-risk for recurrence based on tumor gene expression profiles. Clin Cancer Res. 2005;11:2252-7. PubMed
  • Black D, Bogomolniy F, Robson ME, Offit K, Barakat RR, Boyd J. Evaluation of germline PTEN mutations in endometrial carcinoma patients. Gynecol Oncol. 2004;96:21-4. PubMed
  • Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J. Prevalence of BRCA2 mutations in a hospital-based series of unselected breast cancer cases. J Med Genet. 2005;42:e5. PubMed
  • Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. A gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22:4648-58. PubMed
  • Jazaeri AA, Chandramouli GVR, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med. 2004;2:32. PubMed
  • King TA, Gemignani ML, Li W, Tan LK, Giri DD, Panageas KS, Bogomolniy F, Arroyo C, Olvera N, Robson ME, Offit K, Borgen PI, Boyd J. Aberrant progesterone receptor expression in breast epithelium of BRCA1 mutation carriers. Cancer Res. 2004;64:5051-3.
  • Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and overexpression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol. 2004;93:301-6.
  • Leitao MM, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen R, Dizon DS, Barakat RR, Soslow RA. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004;28:147-59. PubMed
  • Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol. 2004;92:719-25. PubMed
  • Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol. 2003;21:4222-7. PubMed
  • Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 2003;9:4811-8. PubMed
  • Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Begin LR, Offit K, Foulkes WD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutations status and administration of adjuvant treatment. Breast Cancer Res. 2003;6:R8-R17. PubMed
  • Peterlongo P, Nafa K, Lerman GS, Glogowski E, Shia J, Ye TZ, Markowitz AJ, Guillem JG, Kolachana P, Boyd J, Offit K, Ellis NA. MSH6 germline mutations are rare in colorectal cancer families. Int J Cancer. 2003;107:571-9. PubMed
  • Gemignani ML, Bogomolniy F, Lin O, Venkatraman E, Barakat RR, Boyd J. KRAS gene mutations in epithelial ovarian neoplasms. Gynecol Oncol. 2003;90:378-1. PubMed
  • Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet J-S, Hamel N, Paradis A-J, Boyd J, Foulkes WD. The impact of germ-line BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast cancer: 10 year follow up data. Cancer. 2003;97:527-36. PubMed
  • Yossepowitch O, Olvera N, Satagopan JM, Huang H, Jhanwar S, Rapaport B, Boyd J, Offit K. BRCA1 and BRCA2 germline mutations in lymphoma patients. Leukemia Lymphoma. 2003;44:127-31. PubMed
  • Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, Farber D, Greenwood CMT, Bonner JD, Nafa K, Walsh T, Marcus V, Tomsho L, Gebert J, Macrae FA, Gaff CL, Bressac-de Paillerets B, Gregersen PK, Weitzel JN, Gordon PH, MacNamara E, King M-C, Hampel H, de la Chapelle A, Boyd J, Offit K, Rennert G, Chong G, Ellis NA. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet. 2002;71:1395-412. PubMed
  • Gruber SB, Ellis NA, Scott KK, Almong R, Kolachana P, Bonner JD, Kirchoff T,Tomsho LP, Nafa K, Pierce H, Low M, Satagopan J, Rennert H, Huang H, Greenson JK, Groden J, Rappaport B, Shia J, Johnson S, Gregersen PK, Harris CC, Boyd J, Rennert G, Offit K. BLM heterozygosity and the risk of colorectal cancer. Science. 2002;297:2013. PubMed
  • Satagopan J, Boyd J, Kauff N, Robson M, Scheuer L, Narod S, Offit K. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8:3776-81. PubMed
  • Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA-linked and sporadic ovarian cancers. J Natl Cancer Inst. 2002;94:990-1000. PubMed
  • Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin A, Hopper J, Li F, Neuhausen SL, Ozcelik H, Peel D, Santella R, Southey M, van Orsouw NJ, Venter D, Vijg J, Whittemore AS. Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002;20:65-73. PubMed
  • Kauff ND, Satagopan J, Scheuer L, Robson ME, Castiel M, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Offit K. Risk-reducing salpingo-oophorectomy in women with BRCA1 and BRCA2 mutations. N Engl J Med. 2002;346:1609-15. PubMed
  • Levine DA, Federici MG, Reuter VE, Boyd J. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. Gynecol Oncol. 2002;85:431-4. PubMed
  • Scheuer L, Kauff N, Robson M, Kelly B, Barakat R, Satagopan J, Ellis N, Hensley M, Boyd J, Borgen P, Norton L, Offit K. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-8. PubMed
  • Leitao M, Boyd J. Preoperative CA-125 levels in patients with hereditary compared to sporadic ovarian carcinoma. Gynecol Oncol. 2002;84:413-5. PubMed
  • Dowdy SC, O'Kane DJ, Keeney GL, Boyd J, Podratz KC. Telomerase activity in sex cord-stromal tumors of the ovary. Gynecol Oncol. 2001;82:257-60. PubMed
  • Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res. 2001;61:908-11. PubMed
  • Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L, Satagopan J, Offit K, Boyd J. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80:395-8. PubMed
  • Yee CJ, Lin O, Boyd J. Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. J Natl Cancer Inst. 2000;92:1848-9. PubMed
  • The BRCA1 Exon 13 Duplication Screening Group (87 authors). The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet. 2000;67:207-12. PubMed
  • Barakat RR, Federici MG, Saigo PE, Robson ME, Offit K, Boyd J. Absence of premalignant histologic, molecular, or cell biological alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000;89:383-90. PubMed
  • Sonoda Y, Saigo PE, Federici MG, Boyd J. Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. Gynecol Oncol. 2000;76:226-9. PubMed
  • Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. J Am Med Assoc. 2000;283:2260-5.PubMed
Top

Reviews and Editorials (2000 - present)

  • Stany MP, Bonome T, Wamunyokoli F, Zorn K, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008;622:23-33. PubMed
  • Boyd J. Whence epithelial ovarian carcinoma? Gynecol Oncol. 2008;109: 161-3. PubMed
  • Boyd J. An animal model for gynecologic pathology. N Engl J Med. 2005;352:2240-2. PubMed
  • Boyd J. Genetics of familial endometrial cancer: is there more to learn? J Clin Oncol. 2005;21:4570-3. PubMed
  • Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecol Oncol. 2003;88:S8-S10. PubMed
  • Modugno F, Boyd J, Baum A, Bigbee WL, Cramer D, Ferrell R, Gallion HH, Greene MH, Goldman P, Johnson KA, Junker B, Kuller L, Kurman RJ, Maihle N, Narod S, Ness RB, Risch H, Rodriguez G, Sadetzki S, Skates S, Stein M, Weissfeld JL. Ovarian cancer and high-risk women: implications for prevention, screening and early detection. Gynecol Oncol. 2003;91:15-31. PubMed
  • Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol. 2002;1:19-26. PubMed
  • Robson ME, Boyd J, Borgen PI, Cody HS. Hereditary breast cancer. Curr Prob Surg. 2001;38:377-480. PubMed
  • Boyd J. BRCA: The breast, ovarian, and other cancer genes (editorial). Gynecol Oncol. 2001;80:337-40. PubMed
Top

Chapters and Proceedings (2000 - present)

  • Boyd J, Risinger JI, Berchuck A. Oncogenes and tumor suppressor genes. In: Principles and Practice of Gynecologic Oncology, 5th Edition (M Markman, R Barakat, M Randall, eds), pp. 85-112. Lippincott Williams & Wilkens, Philadelphia, 2009.
  • Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup (76 authors). Endometrial cancer state of the science meeting. Int J Gynecol Cancer. 2009;19:134-40.
  • Levine DA, Kauff ND, Boyd J. Genetics of hereditary gynecologic cancers. In: Atlas of Cancer, 2nd Edition (M Markman, ed), pp. 46-53. Current Medicine Group, Philadelphia, 2008.
  • Ashworth A, Balkwill FR, Bast RC, Berek JS, Kaye A, Boyd J, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research: A perspective from the 11th Ovarian Cancer Action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008;108:652-7.
  • Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Bienniel Helene Harris Memorial Trust meeting. Cancer Res. 2006;66:2904-6.
  • Boyd J, Berchuck A. Oncogenes and tumor suppressor genes. In: Principles and Practice of Gynecologic Oncology, 4th Edition (WJ Hoskins, RC Young, M Markman, CA Perez, R Barakat, M Randall, eds), pp. 93-122. Lippincott Williams & Wilkens, Philadelphia, 2005.
  • Boyd J. Hereditary gynecologic cancer syndromes. In: Gynecologic Cancer: Controversies in Management (DM Gershenson, M Gore, WP McGuire, M Quinn, G Thomas, eds), pp. 833-846. Elsevier Science, Philadelphia, 2004.
  • Boyd J. Molecular carcinogenesis. In: Reproductive Medicine. Molecular, Cellular and Genetic Fundamentals (BCJM Fauser, ed), pp. 91-118. Parthenon Publishing, New York, 2003.
  • Boyd J. Genetics of hereditary gynecologic cancers. In: Atlas of Cancer (M Markman, ed), pp. 39-44. Current Medicine, Philadelphia, 2003.
  • Boyd J. Molecular genetics of hereditary ovarian cancer. In: Ovarian Cancer, 2nd Edition (SC Rubin, GP Sutton, eds), pp. 3-17. Lippincott Williams & Wilkens, Philadelphia, 2001.
  • Boyd J, Hamilton TC, Berchuck A. Oncogenes and tumor suppressor genes. In: Principles and Practice of Gynecologic Oncology, 3rd Edition (WJ Hoskins, CA Perez, RC Young, eds), pp. 103-128. Lippincott Williams & Wilkens, Philadelphia, 2000.
Top